Clinical trials: Effects of Immunotherapy
Allergic Rhinitis, Effects of Immunotherapy
Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children
While allergen specific immunotherapy (SIT) is highly effective for allergic diseases in children, the underlying immunological mechanisms are unclear. Regulatory T (Treg) cells may be crucial in induction of tolerance.
- Trial name
- NCT01291381
- Testing
- Dermatophagoides pteronyssinus, Pharmacotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Tongren Hospital
Solid Tumor Malignancies, Solid Cancers
Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study)
Immune Checkpoint Inhibitors (ICI) have revolutionized cancer therapy, providing unprecedented responses in a wide range of malignancies.
- Trial name
- PREDICTO (NCT07192315)
- Testing
- Bloodsampling, Pharyngeal swab sampling, Cuteanous swab sampling
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cat Allergy, Cat Hypersensitivity
A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).
- Trial name
- NCT02311413
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Melanoma Stage IV, Melanoma Stage III
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
- Conditions
- Melanoma Stage IV, Melanoma Stage III, Immunotherapy, Toxicity, Drug
- Trial name
- NCT05652673
- Testing
- nivolumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Pancreatic Cancer
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgical removal) or borderline…
- Trial name
- UVA-PC-PD101 (NCT02305186)
- Testing
- Pembrolizumab, Neoadjuvant Chemoradiation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Craig L Slingluff, Jr
Immunotherapy, Head and Neck Neoplasms
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
This is a phase IB/II trial to examine feasibility and safety of checkpoint blockade (aPD1 with or without aCTLA4) neoadjuvant to standard of care (SOC) in advanced stage head and neck squamous cell carcinoma (HNSCC), a patient…
- Trial name
- IMCISION (NCT03003637)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- The Netherlands Cancer Institute
Non-Small Cell Carcinoma of Lung
Fiber-Boost Randomized Controlled Trial
In the present study 'Fiber-Boost', we investigate how a high-fiber diet affects the immunotherapy of advanced lung cancer and what effects it has on the gut microbiome (i.e., the bacteria in the gut) as well as the immune…
- Trial name
- Fiber-Boost (NCT07483112)
- Testing
- High-fiber diet
- Where
- 4 sites in Switzerland
- Volunteers
- 42 people
- Sponsor
- Cantonal Hospital of St. Gallen
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
This prospective study aims to investigate whether the time of day when immune checkpoint inhibitors (ICIs) are administered affects the efficacy of neoadjuvant immunotherapy in patients with resectable stage II-III non-small…
- Trial name
- LungTime-C02 (NCT07251582)
- Testing
- Time of Day-based Assignment for Infusion of Immune Checkpoint Inhibitor (e.g., toripalimab, or pembrolizumab) + platinum-based chemotherapy
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer, Cardiac Toxicity
Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent…
- Trial name
- NCT06277388
- Testing
- Impedance cardiography
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Sun Yat-sen University
Allergic Asthma
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.
- Trial name
- NCT00492076
- Testing
- Pangramin Plus D. pteronyssinus 100%
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- ALK-Abelló A/S
Type 1 Diabetes Mellitus
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes…
- Trial name
- TN08 (NCT00529399)
- Testing
- GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
- Where
- 15 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Melanoma
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
Background: The gut microbiome is made up microorganisms. These include the good and bad bacteria that live in the digestive tract. Changes in the gut microbiome have been linked to the development of cancer.
- Trial name
- NCT04866810
- Testing
- Intervention Arm, Control
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)